Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Protagonist Therapeutics's Beginning Cash Position for the quarter that ended in Jun. 2026 was MXN3,385 Mil.
Protagonist Therapeutics's quarterly Beginning Cash Position
increased
from Dec. 2025 (MXN2,053 Mil) to Mar. 2026 (MXN2,320 Mil) and
increased
from Mar. 2026 (MXN2,320 Mil) to Jun. 2026 (MXN3,385 Mil).
Protagonist Therapeutics's annual Beginning Cash Position
increased
from Dec. 2023 (MXN2,138 Mil) to Dec. 2024 (MXN3,899 Mil) but then
declined
from Dec. 2024 (MXN3,899 Mil) to Dec. 2025 (MXN1,755 Mil).
Protagonist Therapeutics Beginning Cash Position Related Terms
Protagonist Therapeutics Beginning Cash Position Historical Data
* Premium members only.
The historical data trend for Protagonist Therapeutics's Beginning Cash Position can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Protagonist Therapeutics Beginning Cash Position Chart
What does a Beginning Cash Position of MXN3,385 Mil mean?
Protagonist Therapeutics (MEX:PTGX) has a Beginning Cash Position of MXN3,385 Mil as of Jun. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Protagonist Therapeutics and its competitors.
Is Protagonist Therapeutics' Beginning Cash Position too high?
Protagonist Therapeutics' current Beginning Cash Position is MXN3,385 Mil. Overall, Protagonist Therapeutics has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Protagonist Therapeutics' Beginning Cash Position compare to CRNX and SYRE?
Protagonist Therapeutics' Beginning Cash Position of MXN3,385 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Protagonist Therapeutics and its competitors. Protagonist Therapeutics's current Beginning Cash Position is MXN3,385 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Protagonist Therapeutics stock overvalued right now?
Protagonist Therapeutics (MEX:PTGX) has a current Beginning Cash Position of MXN3,385 Mil. The stock's GF Value™ is MXN891.21, compared to a current price of MXN1,565.33 — trading 75.6% above its estimated fair value. The current Beginning Cash Position is MXN3,385 Mil. Protagonist Therapeutics' overall GF Score™ is 47/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Protagonist Therapeutics (MEX:PTGX), the current Beginning Cash Position is MXN3,385 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Protagonist Therapeutics (MEX:PTGX) Overvalued in 2026?
Based on GuruFocus' analysis, Protagonist Therapeutics stock appears to be overvalued.
The current stock price of MXN1,565.33 is trading 75.6% above its estimated GF Value™ of MXN891.21.
Key valuation signals for MEX:PTGX:
Beginning Cash Position: MXN3,385 Mil
GF Value™: MXN891.21 vs. price of MXN1,565.33 (75.6% above fair value)
No single metric tells the full story. See the MEX:PTGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
47GF Score
Get the complete analysis for MEX:PTGX
Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:PTGX has been successfully added to your 
